Asterias Biotherapeutics, Inc. (NYSE:AST) insider have most recently took part in a trading activity. On Dec 26, 2017 Mulroy Michael H., President and CEO bought 2,247 shares having total worth of $4,988 at the price of $2.22 per share, following the transaction a total of 7,799 shares owned by Mulroy Michael H.. Before this latest buy, Mulroy Michael H. purchased AST at 2 other times during the past twelve months, for a total investment of $9,948 at an average of $2.48 per share.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 buy trades. Furthermore, over the past 12 months , the stock was traded 6 times by insiders. In 4 of these trades, the insider was a seller while an employee of the company was the buyer in 2 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Asterias Biotherapeutics, Inc. (NYSE:AST) traded up 2.27% on Dec 27, 2017, hitting $2.25. 159,133 shares of the company’s stock traded hands. Asterias Biotherapeutics, Inc. has a 52 week low of $2 and a 52 week high of $5.65. The company’s market cap is $207 million.
Asterias Biotherapeutics, Inc. (NYSE:AST) last announced its earnings results on Nov 14, 2017. The company reported -0.14 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.14. The company had revenue of $2 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.24 earnings per share. The company’s revenue for the quarter was down 19% on a year-over-year basis.
|earnings per share||-0.14||-0.18||-0.13||-0.20||-0.24||0.00||-0.27||-0.13|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018